Human 3 with Brom and Sam

Today’s guests are MJ Antonini & Nicki Driscoll, the founders of NeuroBionics, a neurotech startup out of MIT. NeuroBionics is making Deep Brain Stimulation minimally invasive though the development of nano fibers that are 10X thinner than traditional Deep Brain Stimulation leads - allowing them to be inserted endovascularly into the brain. Check out NeuroBionics at https://neurobionics.io/

Lars Wilde is the cofounder of Pangea Bio - startup that uses AI to identify natural compounds and traditional remedies that may have medical applications. Prior to starting Pangea, Lars cofounded Compass Pathways and ATAI life sciences, both of which IPOd on the NASDAQ.

Can a succulent plant from South Africa treat premature ejaculation? John Boghossian and Dr Ryan Protzko from Kadence Bio think so. www.kadencebio.com

Can brain implants treat your depression? Ok, technically this would be a skull implant, not a brain implant - but still! Jacob Robinson from Motif Neurotech discusses the future of minimally invasive electronic medicine from mental health and beyond. This is a crossover episode from the Business Trip podcast.

Dr. Elliot Marseille, UC Berkeley Healthcare Economist, discusses the economic and financial aspects of psychedelic therapies. They explore the cost, insurance coverage, and value of a psychedelic experience. They also highlight the cost-effectiveness of MDMA therapy for PTSD and the potential future availability and affordability of psychedelic therapies.

🤖 ChatGPT & Dall-E today - misinformation, bias & worker displacement tomorrow. In a world where artificial intelligence is becoming increasingly advanced, it's more important than ever to ensure that AI systems are aligned with our values and behave in ways that are safe for humanity. But what exactly does it mean to align an AI system, and how do we go about ensuring its safety?    Here to answer these questions and more (including the most important question: will AIs take psychedelics?) is Ramsay Brown. Ramsay is the Founder of the AI Responsibility Lab (AIRL). AIRL builds venture-scale deep tech solutions for AI Safety and AI Resilience. AIRL's flagship product, Mission Control, integrates Responsible AI training, AI Risk Management, and AI Governance orchestration to drive fairness, explainability, and trust throughout the entire AI lifecycle.   Check out AIRL here: https://www.takecontrol.ai/   Ramsay on Twitter: https://twitter.com/_ramsaybrown  Brom on twitter: https://twitter.com/therealbrom 5:30 - What are the major concerns in AI safety?  10:30 - Examples of AI gone bad   16:00 - What is the hardest part of AI alignment?  21:00 - What is Ramsay’s unique angle on AI alignment?   24:00 - Is the world ready for conversations about responsible AI?    25:30 - Who is responsible for responsible AI?   32:00 - What regulations would Ramsay put into place?   41:00 - Eliezer Yudkowsky  47:00 - The era of synthetic labor  55:00 - The Turing Test is a red herring   1:04:00 - What jobs are safe from the AI takeover?   1:14:00 - Will machines do psychedelics?

Zach Haigney is the author of The Trip Report, a newsIetter that covers the emerging psychedelic science, medicine, and policy landscape.  In this conversation, Zach and Brom discuss emerging trends, questions and hot topics in the psychedelics industry including:   The lines of tension between Drug Development and Drug Policy Directive vs Non-Directive Psychedelic Therapy  How Psychedelics are inverting the traditional drug development model  What business models will emerge in psychedelics?  Are fears about VC investment in psychedelics overstated?   How psychedelics can be thought of as a form of hormetic therapy  What can psychedelics be used for outside of treating mental health issues?   We also discuss The Trip Report's recent acquisition by Beckley Waves.   You can check out The Trip Report here:  https://thetripreport.substack.com/  Follow Zach on Twitter: https://twitter.com/zach_haigney Follow Brom on Twitter:  https://twitter.com/therealbrom  Make sure to subscribe to the show!

Sam Banister is a medicinal chemist and co-founder of Psylo.  Psylo is an Australian psychedelic biotech company using machine learning assisted drug design techniques to developing novel psychedelic medicines to treat mental illness.    Sam is here to help us understand how new chemical entities are reshaping the psychedelic field; how novel psychedelic molecules are made,  and how new chemical entities are going to play a dominant role in the future of psychedelic medicine.   Make sure to subscribe to the show!   Follow Brom on twitter: https://twitter.com/therealbrom Follow Sam on twitter: https://twitter.com/samuel_b_phd Brom's VC Fund:  https://www.empath.vc Highlighted Timestamps:   06:12 - Are next generation psychedelics taking over in 10 years?   16:10 - What is the process like for creating a new chemical entities?   50:39 - Psychedelics vs Cannabis: New drug discoveries

Mendel Kaelen is the CEO of Wavepaths.  Prior to founding Wavepaths, Mendel Kaelen worked as a PhD and postdoctoral neuroscientist at Imperial College London since 2012, where his research was the one of the first to demonstrate music’s central role in psychedelic therapies.  Wavepaths is a software platform that generates personalized, optimal music for psychedelic therapy.     0:00 - Why work on music and psychedelics?  3:30 - Highlights of Mendel’s academic career.  7:30 - Is there a universal “best” music for psychedelic therapy?  How to design a psychedelic therapy playlist.  11:30 - What does the importance of music personalization mean for group psychedelic sessions?   16:00 - Should music for psychedelics be “familiar” to the patient, or novel?  20:00 - Vocals vs no vocals?  It’s not that simple.   23:00 - Directive vs non-directive and concrete vs fluid music.  25:00 - Is the “right” music for psychedelics consistent across different drugs?   28:00 - How did Mendel switch from academia to startup founder.  30:30 - What is Wavepaths?   35:30 - Who is Wavepaths for?   37:00 - How do you sell music for psychedelic therapy?   39:00 - Surprising insights from Wavepaths customers?   43:30 - How does Wavepaths use biofeedback?   46:00 - Wavepaths direct to consumer.   49:45 - Startup life vs academia.  51:00 - Virtual reality and psychedelic therapy.

Tom Feegel is the Founder and CEO of Beond.  Beond exists to help end the opiate addiction epidemic with safe ibogaine treatment.   In this episode Tom speaks on the severity of the opioid epidemic and explains how ibogaine assisted therapy can help heal those who are suffering from addiction.  Tom gets into his personal story, how Ibogaine helped someone in his family, the economics of addiction treatment and Beond's plans to scale into a global operation.     https://www.beond.us